KRAS and pancreatic neoplasm: Experiments with two KRAS G12C inhibition‐sensitive CDX models Mia PaCa‐2 (Pancreatic cancer) and NCI‐H358 (NSCLC) were used to evaluate the potential therapeutic utility of the AMG510‐IN10018 combination.